Cisco, Gilead: After-Hours Trading
Rabu, 10 Agustus 2011 by Android Blackberry
Cisco, Gilead: After-Hours Trading
Shares of Cisco Systems(CSCO) advanced on heavy volume in Wednesday's after-hours session right after the Dow component delivered an above-consensus quarterly profit and also a favorable outlook for the current period.
The San Jose, Calif.-based networking giant posted non-GAAP earnings of $2.two billion, or 40 cents a share, for its fiscal fourth quarter ended on June 30, on revenue of $11.2 billion, ahead of the typical estimate of analysts polled by Thomson Reuters for a profit of 38 cents a share inside the quarter on revenue of $10.97 billion.
The stock was last quoted at $14.81, up 8%, on volume of extra than 16 million, based on Nasdaq.com. Based on a regular session close at $13.73 on Tuesday, the shares are down far more than 30% so far in 2011. The after-hours high is $15.49.
"We've created considerable progress on our comprehensive action program to position ourselves for our subsequent stage of growth and profitability, even though delivering solid monetary outcomes in Q4," said John Chambers, the company's chairman and CEO, in a statement. "As we get started our subsequent fiscal year, you will see a incredibly focused, agile, lean and aggressive business, that is laser focused on helping our clients use intelligent networks to transform their companies."
TheStreet covered Cisco's conference call in a live weblog, and reported that Chambers has forecast revenue growth of between 1-and-4% for its fiscal fourth quarter ending in September, besting Wall Street's flat view.
The news gave a slight lift to Cisco competitors Juniper Networks(JNPR_), up 1.6% to $21 on volume of a lot more than 130,000; and Riverbed Technology(RVBD_), rising 1.2% to $23.27 on volume of about 60,000.
Gilead Sciences
Shares of Gilead Sciences(GILD_) got a lift in late trades after the company said it and partner Johnson & Johnson(JNJ_) had received marketing approval from the Food and Drug Administration of their Complera once-a-day tablet for the HIV-1 infection in treatment-naïve adults.
Gilead's stock was last up 2.4% to $36.20 on volume of more than 670,000. Based on a typical session close at $35.34, the shares were up 5% year-to-date.
Gilead reached a deal to collaborate with J&J's Tibotec unit on a single-pill HIV treatment in July 2009.Cisco, Gilead: After-Hours Trading
Shares of Cisco Systems(CSCO) advanced on heavy volume in Wednesday's after-hours session right after the Dow component delivered an above-consensus quarterly profit and also a favorable outlook for the current period.
The San Jose, Calif.-based networking giant posted non-GAAP earnings of $2.two billion, or 40 cents a share, for its fiscal fourth quarter ended on June 30, on revenue of $11.2 billion, ahead of the typical estimate of analysts polled by Thomson Reuters for a profit of 38 cents a share inside the quarter on revenue of $10.97 billion.
The stock was last quoted at $14.81, up 8%, on volume of extra than 16 million, based on Nasdaq.com. Based on a regular session close at $13.73 on Tuesday, the shares are down far more than 30% so far in 2011. The after-hours high is $15.49.
"We've created considerable progress on our comprehensive action program to position ourselves for our subsequent stage of growth and profitability, even though delivering solid monetary outcomes in Q4," said John Chambers, the company's chairman and CEO, in a statement. "As we get started our subsequent fiscal year, you will see a incredibly focused, agile, lean and aggressive business, that is laser focused on helping our clients use intelligent networks to transform their companies."
TheStreet covered Cisco's conference call in a live weblog, and reported that Chambers has forecast revenue growth of between 1-and-4% for its fiscal fourth quarter ending in September, besting Wall Street's flat view.
The news gave a slight lift to Cisco competitors Juniper Networks(JNPR_), up 1.6% to $21 on volume of a lot more than 130,000; and Riverbed Technology(RVBD_), rising 1.2% to $23.27 on volume of about 60,000.
Gilead Sciences
Shares of Gilead Sciences(GILD_) got a lift in late trades after the company said it and partner Johnson & Johnson(JNJ_) had received marketing approval from the Food and Drug Administration of their Complera once-a-day tablet for the HIV-1 infection in treatment-naïve adults.
Gilead's stock was last up 2.4% to $36.20 on volume of more than 670,000. Based on a typical session close at $35.34, the shares were up 5% year-to-date.
Gilead reached a deal to collaborate with J&J's Tibotec unit on a single-pill HIV treatment in July 2009.Cisco, Gilead: After-Hours Trading
